For cancer patients, losing hair during chemotherapy is an unfortunate, but expected, side effect. What isn’t expected is that the hair loss will be permanent. And yet, that’s exactly what has happened to some cancer survivors who took the drug Taxotere.
While hair typically grows back after the end of chemotherapy, scores of people who took Taxotere now find themselves afflicted with alopecia, otherwise known as permanent hair loss. To add insult to injury, many of these people say they were never warned their hair might not grow back, despite the fact the manufacturer has allegedly known about the possibility for decades.
Now, patients are joining together to take legal against Sanofi, the manufacturer. If you have experienced permanent hair loss after taking Taxotere, you too many be eligible to join this group in seeking financial compensation.
Patients Unaware of Taxotere Side Effect
Taxotere, also known as Docetaxel, was originally approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung cancer in 1999. The FDA later expanded its approval to cover the treatment of prostrate, breast, gastric and head and neck cancers. Of these, it may have been most widely used to treat breast cancer patients.
Women who were prescribed Taxotere for the treatment of breast cancer had another option. The drug Paclitaxel is a similar form of chemotherapy although it must be administered each week while Taxotere is typically given every three weeks. Patients and doctors may have chosen Taxotere for convenience, but in court filings, women say they would have made a different treatment decision if they had known permanent hair loss could be a side effect.
In 2015, the FDA added permanent hair loss to the drug’s warning label as a potential side effect. However, that came too late for people who had been already taken Taxotere and had since developed alopecia.
Plaintiffs: Company Should Have Known About Taxotere Side Effects
More than 800 Taxotere lawsuits have been filed so far, and the courts have approved multidistrict litigation (MDL) to bring all those cases together in the U.S. District Court, Eastern District of Louisiana.
Plaintiffs in the Taxotere MDL argue Sanofi – and Aventis before it – knew about the possibility of permanent hair loss and did not warn patients. They cite multiple studies which would have alerted the manufacturer to the problem. These include research from the late 1990s which indicated 9.2 percent of Taxotere users experienced alopecia for 10 years or longer.
Individuals negatively affected by the drug are now taking legal action against Sanofi and are filing for financial compensation from the pharmaceutical company.
Did you experience permanent hair loss after taking Taxotere?
The U.S. District Court is currently accepting complaints from plaintiffs who want to be a part of the Taxotere MDL. What does that mean for you? It means that now may be a good time to have your claim reviewed for inclusion as part of the case against Sanofi.
LegalDirect can connect you to a Taxotere attorney for a free case review. There is no cost or obligation.
Complete the form on this page to be quickly connected to a Taxotere lawyer for your FREE consultation.
If you’ve experienced permanent hair loss that may be attributed to Taxotere, isn’t it time to explore your options for compensation?